Ticker brief

ARCT

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
22
authors 14d
12
crowd 14d
+0.5σ

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-25 · now +0.40 (−1 bearish … +1 bullish)
Who spoke12
authorgradetrader scoresignalsmean sent
@Brad_E_SchulzC·5+0.45
@fundmyfundB-1.584+0.30
@Markadiusz45C+1.182+0.20
@PharmdcaC+0.822+0.20
@MrStockLockPro1C-0.942+0.42
@BiopharmIQB·1+0.00
@OTR444C-1.391+0.20
@Analytica_XB+1.031+0.30
@TrendSpiderC-1.011+0.30
@OptionsFlowBossC·1+0.20
@BPharmCatalystC·1-0.40
@WallStDiariesC-0.201+0.45
Recent signals22of 22 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-25@Brad_E_Schulz+0.15Lists stocks up at least 4% on 1.5x or greater average volume.·
2026-08-25@fundmyfund+0.65Says ARCT's exceptional strength is continuing.·
2026-08-24@fundmyfund+0.45Observes ARCT strength and attributes it tentatively to unspecified MRNA news.·
2026-08-24@Brad_E_Schulz+0.30Lists stocks up at least 4% with elevated volume multiples.·
2026-08-22@WallStDiaries+0.45Arcturus rose more than 60% for the week amid improving biotech sentiment.·
2026-08-21@Brad_E_Schulz+0.40Reports positive sector performance and names leading stocks gaining at least 5%.·
2026-08-21@Brad_E_Schulz+0.70Lists leading stocks up at least 4% on at least 1.5 times average daily volume.·
2026-08-21@BPharmCatalyst-0.40ARCT reported a wider Q2 loss and lower collaboration revenue, partly offset by cash runway and catalysts.·
2026-08-21@fundmyfund-0.35Calls ARCT's pre-news weekly chart incredibly poor and attributes the move to luck.·
2026-08-21@fundmyfund+0.45Quantifies ARCT and MRNA gains following positive late-stage cancer-vaccine results.·
2026-08-21@OptionsFlowBoss+0.20Lists unusually high bullish options-volume multiples; later bearish remark is not assigned to named stocks.·
2026-08-21@Brad_E_Schulz+0.70Lists intraday leaders up at least 4% on at least 1.5 times average volume.·
2026-08-19@MrStockLockPro1+0.40Watchlist recap reports completed percentage moves for four stocks.·
2026-08-19@TrendSpider+0.30AI scan identifies public companies advancing mRNA technology after a cancer-vaccine breakthrough.·
2026-08-19@Analytica_X+0.30Reports positive Phase 3 cancer-vaccine results and bullish readthroughs for personalized vaccine platforms·
2026-08-19@Pharmdca+0.25Highlights ARCT's 27% short float alongside MRNA, implying squeeze sensitivity.·
2026-08-19@MrStockLockPro1+0.45Morning watchlist gives conditional breakout entries, targets and stops but not the author's entry intent.·
2026-08-19@Pharmdca+0.15Reports successful Phase 3 melanoma endpoints for Moderna and Merck, plus biotech sympathy moves and an IVVD catalyst.·
2026-08-19@OTR444+0.20Publishes a multi-name momentum watchlist with catalysts and market-cap data·
2026-08-19@Markadiusz45+0.15Lists neglected RNA-related charts generated by ChatGPT.·
2026-08-19@Markadiusz45+0.25Suggests an emerging RNA-stock season and supplies a multi-name thematic basket.·
2026-08-16@BiopharmIQ+0.00Q3 biotech clinical-catalyst watchlist names phases and timing.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.